Acadia Pharmaceuticals ACAD Return on equity

Return on equity at other companies

BiogenBIIB

4.8%-4.3pp

Neurocrine BiosciencesNBIX

22.5%+10.1pp

Taysha Gene Therapies, Inc.TSHA

-97.3%-27.3pp

Zevra Therapeutics, Inc.ZVRA

34.8%+31.3pp

Rapport Therapeutics, Inc.RAPP

-40%+22.3pp

Amneal Pharmaceuticals, Inc.AMRX

-52.8%-12.7pp

FAQ

What is Acadia Pharmaceuticals's return on equity?

Acadia Pharmaceuticals (ACAD) reported return on equity of 35.7% in Q2 2026.

How has Acadia Pharmaceuticals's return on equity changed year-over-year?

Acadia Pharmaceuticals's return on equity increased by 7.7% year-over-year, from 33.2% to 35.7%.

What is the long-term trend for Acadia Pharmaceuticals's return on equity?

Over 5 years (2020 to 2025), Acadia Pharmaceuticals's return on equity has grown at a -1.2% compound annual growth rate (CAGR), from -42.5% to 39.9%.

What does return on equity mean?

Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.